Pharmaceutical Companies
Make Therapies “Sticky”
With SaMD and DTx
Rapidly scale your product pipeline of SaMD and Digital Therapeutics that engage patients and demonstrably improve outcomes.
As therapy specialists, you know that
innovations in patient treatment are
essential for success.
SaMD and Digital Therapeutics (DTx), such as companion applications for drugs or diagnostics, can create “sticky” treatments that promote patient adherence – and ultimately improve real world outcomes and create important new revenue streams for your business. But to get the most out of digital innovations across the clinical domains that you treat, and at speed, you need an experienced partner that knows how to Build, Evolve and Scale.
Orthogonal has a proven, repeatable process for developing SaMD that takes advantage of modern software development methods while staying compliant. Our methods reduce the timelines for developing and updating products, drive patient engagement and get you to regulatory submission faster.
We understand the different needs and constraints of groups within pharmaceutical firms, including clinical trials, commercial and digital health R&D. Our process is designed to address the specific requirements of each group in complementary ways.
What’s more, Orthogonal can take a single SaMD or DTx platform and rapidly scale it across multiple clinical domains. By identifying reusable elements, we streamline the process of creating unique software components that meet the needs of the specific patient profile, without having to start from scratch with each new area of treatment.
What Our Clients Say
“We needed a SaMD partner equally versed in medical device software development and modern software engineering. Orthogonal clearly crosses that bar, and has been an invaluable asset for Boehringer Ingelheim Digital.”
Janet Maldonado
Head of Engineering, Boehringer Ingelheim Digital
